Pharvaris (PHVS) Competitors

$30.40 -0.30 (-0.98%)

Closing price 05/15/2026 04:00 PM Eastern

Extended Trading

$30.43 +0.03 (+0.10%)

As of 05/15/2026 04:13 PM Eastern

PHVS vs. NUVL, PCVX, QGEN, KYMR, and SYRE

Should you buy Pharvaris stock or one of its competitors? MarketBeat compares Pharvaris with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with Pharvaris include Nuvalent (NUVL), Vaxcyte (PCVX), Qiagen (QGEN), Kymera Therapeutics (KYMR), and Spyre Therapeutics (SYRE). These companies are all part of the "pharmaceutical products" industry.

How does Pharvaris compare to Nuvalent?

Pharvaris (NASDAQ:PHVS) and Nuvalent (NASDAQ:NUVL) are both mid-cap medical companies, but which is the superior investment? We will contrast the two companies based on the strength of their valuation, earnings, profitability, risk, institutional ownership, media sentiment, analyst recommendations and dividends.

Pharvaris currently has a consensus price target of $49.18, suggesting a potential upside of 61.78%. Nuvalent has a consensus price target of $137.25, suggesting a potential upside of 34.16%. Given Pharvaris' higher probable upside, analysts clearly believe Pharvaris is more favorable than Nuvalent.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Pharvaris	1 Sell rating(s)	2 Hold rating(s)	10 Buy rating(s)	0 Strong Buy rating(s)	2.69
Nuvalent	1 Sell rating(s)	0 Hold rating(s)	16 Buy rating(s)	0 Strong Buy rating(s)	2.88

Nuvalent is trading at a lower price-to-earnings ratio than Pharvaris, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Pharvaris	N/A	N/A	-$198.79M	-$3.18	N/A
Nuvalent	N/A	N/A	-$425.38M	-$6.06	N/A

97.3% of Nuvalent shares are owned by institutional investors. 11.8% of Pharvaris shares are owned by company insiders. Comparatively, 5.0% of Nuvalent shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock is poised for long-term growth.

Nuvalent's return on equity of -40.11% beat Pharvaris' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Pharvaris	N/A	-67.56%	-61.13%
Nuvalent	N/A	-40.11%	-35.43%

Pharvaris has a beta of -2.34, suggesting that its stock price is 334% less volatile than the broader market. Comparatively, Nuvalent has a beta of 1.15, suggesting that its stock price is 15% more volatile than the broader market.

In the previous week, Nuvalent had 4 more articles in the media than Pharvaris. MarketBeat recorded 15 mentions for Nuvalent and 11 mentions for Pharvaris. Pharvaris' average media sentiment score of 0.50 beat Nuvalent's score of 0.05 indicating that Pharvaris is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Pharvaris	0 Very Positive mention(s)	3 Positive mention(s)	5 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Nuvalent	1 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

Summary

Nuvalent beats Pharvaris on 7 of the 13 factors compared between the two stocks.

How does Pharvaris compare to Vaxcyte?

Pharvaris (NASDAQ:PHVS) and Vaxcyte (NASDAQ:PCVX) are both mid-cap medical companies, but which is the superior investment? We will contrast the two companies based on the strength of their valuation, earnings, profitability, risk, institutional ownership, media sentiment, analyst recommendations and dividends.

Pharvaris currently has a consensus price target of $49.18, suggesting a potential upside of 61.78%. Vaxcyte has a consensus price target of $86.00, suggesting a potential upside of 64.15%. Given Vaxcyte's higher probable upside, analysts clearly believe Vaxcyte is more favorable than Pharvaris.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Pharvaris	1 Sell rating(s)	2 Hold rating(s)	10 Buy rating(s)	0 Strong Buy rating(s)	2.69
Vaxcyte	1 Sell rating(s)	1 Hold rating(s)	6 Buy rating(s)	0 Strong Buy rating(s)	2.63

Pharvaris is trading at a lower price-to-earnings ratio than Vaxcyte, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Pharvaris	N/A	N/A	-$198.79M	-$3.18	N/A
Vaxcyte	N/A	N/A	-$766.63M	-$6.88	N/A

96.8% of Vaxcyte shares are owned by institutional investors. 11.8% of Pharvaris shares are owned by company insiders. Comparatively, 3.1% of Vaxcyte shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock is poised for long-term growth.

Vaxcyte's return on equity of -32.51% beat Pharvaris' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Pharvaris	N/A	-67.56%	-61.13%
Vaxcyte	N/A	-32.51%	-29.51%

Pharvaris has a beta of -2.34, suggesting that its stock price is 334% less volatile than the broader market. Comparatively, Vaxcyte has a beta of 1.3, suggesting that its stock price is 30% more volatile than the broader market.

In the previous week, Pharvaris had 4 more articles in the media than Vaxcyte. MarketBeat recorded 11 mentions for Pharvaris and 7 mentions for Vaxcyte. Vaxcyte's average media sentiment score of 0.85 beat Pharvaris' score of 0.50 indicating that Vaxcyte is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Pharvaris	0 Very Positive mention(s)	3 Positive mention(s)	5 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Vaxcyte	2 Very Positive mention(s)	0 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Summary

Vaxcyte beats Pharvaris on 7 of the 13 factors compared between the two stocks.

How does Pharvaris compare to Qiagen?

Pharvaris (NASDAQ:PHVS) and Qiagen (NYSE:QGEN) are both mid-cap medical companies, but which is the superior investment? We will contrast the two companies based on the strength of their valuation, earnings, profitability, risk, institutional ownership, media sentiment, analyst recommendations and dividends.

In the previous week, Pharvaris and Pharvaris both had 11 articles in the media. Pharvaris' average media sentiment score of 0.50 beat Qiagen's score of 0.33 indicating that Pharvaris is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Pharvaris	0 Very Positive mention(s)	3 Positive mention(s)	5 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Qiagen	0 Very Positive mention(s)	1 Positive mention(s)	8 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Neutral

Qiagen has higher revenue and earnings than Pharvaris. Pharvaris is trading at a lower price-to-earnings ratio than Qiagen, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Pharvaris	N/A	N/A	-$198.79M	-$3.18	N/A
Qiagen	$2.09B	3.25	$424.88M	$1.91	17.28

Pharvaris currently has a consensus price target of $49.18, suggesting a potential upside of 61.78%. Qiagen has a consensus price target of $46.38, suggesting a potential upside of 40.53%. Given Pharvaris' stronger consensus rating and higher probable upside, analysts clearly believe Pharvaris is more favorable than Qiagen.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Pharvaris	1 Sell rating(s)	2 Hold rating(s)	10 Buy rating(s)	0 Strong Buy rating(s)	2.69
Qiagen	0 Sell rating(s)	7 Hold rating(s)	4 Buy rating(s)	1 Strong Buy rating(s)	2.50

70.0% of Qiagen shares are owned by institutional investors. 11.8% of Pharvaris shares are owned by company insiders. Comparatively, 9.0% of Qiagen shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock is poised for long-term growth.

Pharvaris has a beta of -2.34, suggesting that its stock price is 334% less volatile than the broader market. Comparatively, Qiagen has a beta of 0.64, suggesting that its stock price is 36% less volatile than the broader market.

Qiagen has a net margin of 19.16% compared to Pharvaris' net margin of 0.00%. Qiagen's return on equity of 14.40% beat Pharvaris' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Pharvaris	N/A	-67.56%	-61.13%
Qiagen	19.16%	14.40%	8.40%

Summary

Qiagen beats Pharvaris on 10 of the 15 factors compared between the two stocks.

How does Pharvaris compare to Kymera Therapeutics?

Pharvaris (NASDAQ:PHVS) and Kymera Therapeutics (NASDAQ:KYMR) are both mid-cap medical companies, but which is the better investment? We will compare the two businesses based on the strength of their dividends, risk, earnings, profitability, institutional ownership, valuation, media sentiment and analyst recommendations.

In the previous week, Pharvaris and Pharvaris both had 11 articles in the media. Pharvaris' average media sentiment score of 0.50 beat Kymera Therapeutics' score of 0.30 indicating that Pharvaris is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Pharvaris	0 Very Positive mention(s)	3 Positive mention(s)	5 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Kymera Therapeutics	2 Very Positive mention(s)	1 Positive mention(s)	6 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

Pharvaris has higher earnings, but lower revenue than Kymera Therapeutics. Kymera Therapeutics is trading at a lower price-to-earnings ratio than Pharvaris, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Pharvaris	N/A	N/A	-$198.79M	-$3.18	N/A
Kymera Therapeutics	$39.21M	172.47	-$311.35M	-$3.57	N/A

Pharvaris currently has a consensus price target of $49.18, suggesting a potential upside of 61.78%. Kymera Therapeutics has a consensus price target of $118.10, suggesting a potential upside of 43.65%. Given Pharvaris' higher probable upside, equities research analysts clearly believe Pharvaris is more favorable than Kymera Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Pharvaris	1 Sell rating(s)	2 Hold rating(s)	10 Buy rating(s)	0 Strong Buy rating(s)	2.69
Kymera Therapeutics	1 Sell rating(s)	0 Hold rating(s)	21 Buy rating(s)	1 Strong Buy rating(s)	2.96

Pharvaris has a beta of -2.34, suggesting that its stock price is 334% less volatile than the broader market. Comparatively, Kymera Therapeutics has a beta of 2.06, suggesting that its stock price is 106% more volatile than the broader market.

Pharvaris has a net margin of 0.00% compared to Kymera Therapeutics' net margin of -611.94%. Kymera Therapeutics' return on equity of -24.71% beat Pharvaris' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Pharvaris	N/A	-67.56%	-61.13%
Kymera Therapeutics	-611.94%	-24.71%	-22.05%

Summary

Kymera Therapeutics beats Pharvaris on 7 of the 13 factors compared between the two stocks.

How does Pharvaris compare to Spyre Therapeutics?

Pharvaris (NASDAQ:PHVS) and Spyre Therapeutics (NASDAQ:SYRE) are both mid-cap medical companies, but which is the better investment? We will compare the two businesses based on the strength of their dividends, risk, earnings, profitability, institutional ownership, valuation, media sentiment and analyst recommendations.

In the previous week, Pharvaris had 4 more articles in the media than Spyre Therapeutics. MarketBeat recorded 11 mentions for Pharvaris and 7 mentions for Spyre Therapeutics. Spyre Therapeutics' average media sentiment score of 1.31 beat Pharvaris' score of 0.50 indicating that Spyre Therapeutics is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Pharvaris	0 Very Positive mention(s)	3 Positive mention(s)	5 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Spyre Therapeutics	4 Very Positive mention(s)	1 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Spyre Therapeutics has higher revenue and earnings than Pharvaris. Spyre Therapeutics is trading at a lower price-to-earnings ratio than Pharvaris, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Pharvaris	N/A	N/A	-$198.79M	-$3.18	N/A
Spyre Therapeutics	$890K	7,310.17	-$155.20M	-$2.08	N/A

Pharvaris currently has a consensus price target of $49.18, suggesting a potential upside of 61.78%. Spyre Therapeutics has a consensus price target of $90.25, suggesting a potential upside of 20.46%. Given Pharvaris' higher probable upside, equities research analysts clearly believe Pharvaris is more favorable than Spyre Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Pharvaris	1 Sell rating(s)	2 Hold rating(s)	10 Buy rating(s)	0 Strong Buy rating(s)	2.69
Spyre Therapeutics	1 Sell rating(s)	0 Hold rating(s)	10 Buy rating(s)	2 Strong Buy rating(s)	3.00

80.4% of Spyre Therapeutics shares are owned by institutional investors. 11.8% of Pharvaris shares are owned by insiders. Comparatively, 15.7% of Spyre Therapeutics shares are owned by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock is poised for long-term growth.

Pharvaris has a beta of -2.34, suggesting that its stock price is 334% less volatile than the broader market. Comparatively, Spyre Therapeutics has a beta of 3.12, suggesting that its stock price is 212% more volatile than the broader market.

Spyre Therapeutics' return on equity of -42.88% beat Pharvaris' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Pharvaris	N/A	-67.56%	-61.13%
Spyre Therapeutics	N/A	-42.88%	-27.76%

Summary

Spyre Therapeutics beats Pharvaris on 11 of the 14 factors compared between the two stocks.

Get Pharvaris News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding PHVS and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

PHVS vs. The Competition

Export

Metric	Pharvaris	MED Industry	Medical Sector	NASDAQ Exchange
Market Cap	$2.01B	$3.38B	$6.42B	$12.48B
Dividend Yield	N/A	2.32%	2.80%	5.25%
P/E Ratio	-9.56	18.34	20.38	25.24
Price / Sales	N/A	294.63	566.15	82.24
Price / Cash	N/A	124.05	43.04	56.04
Price / Book	7.19	6.63	9.87	6.90
Net Income	-$198.79M	$24.40M	$3.57B	$334.66M
7 Day Performance	1.03%	4.15%	0.31%	0.13%
1 Month Performance	5.63%	-2.65%	-1.27%	1.11%
1 Year Performance	83.57%	62.87%	33.54%	30.62%

Pharvaris Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
PHVS Pharvaris	3.8387 of 5 stars	$30.40 -1.0%	$49.18 +61.8%	+91.1%	$2.01B	N/A	N/A	30	Earnings Report Analyst Forecast
NUVL Nuvalent	2.848 of 5 stars	$102.75 -1.7%	$137.25 +33.6%	+44.1%	$8.08B	N/A	N/A	40	Analyst Revision
PCVX Vaxcyte	2.8793 of 5 stars	$54.03 +0.1%	$86.00 +59.2%	+69.5%	$7.80B	N/A	N/A	160	Options Volume
QGEN Qiagen	4.5519 of 5 stars	$33.67 +3.2%	$46.38 +37.8%	-25.7%	$6.94B	$2.09B	17.58	5,654	Dividend Increase Analyst Downgrade
KYMR Kymera Therapeutics	2.3374 of 5 stars	$83.62 -0.6%	$118.10 +41.2%	+173.9%	$6.88B	$39.21M	N/A	170

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:PHVS) was last updated on 5/16/2026 by MarketBeat.com Staff.

From Our Partners

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Pharvaris (PHVS) Competitors